Revolution Medicines, Inc. (NASDAQ: RVMD - Get Free Report) insider Alan Sandler sold 341 shares of

Revolution Medicines, Inc. (NASDAQ: RVMD - Get Free Report) CFO Jack Anders sold 4,053 shares of the

Axsome Therapeutics is generating rapid revenue growth through its expanding portfolio of commercial

Engineers Gate Manager LP increased its stake in shares of Revolution Medicines, Inc. (NASDAQ: RVMD)

Revolution Medicines, Inc. (NASDAQ: RVMD - Get Free Report) insider Stephen Kelsey sold 92,531 share

Revolution Medicines validated its approach to treating certain cancers with a recent regulatory app

Concurrent Investment Advisors LLC bought a new stake in Revolution Medicines, Inc. (NASDAQ: RVMD) d

REDWOOD CITY, Calif., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD),

Revolution Medicines, Inc. (NASDAQ: RVMD - Get Free Report) Director Lorence Kim sold 17,090 shares

Amgen maintains a massive global footprint and generated over $8.1 billion in free cash flow during

Morgan Stanley analyst Sean Laaman initiates coverage on Revolution Medicines (NASDAQ:RVMD) with

Arizona State Retirement System boosted its holdings in shares of Revolution Medicines, Inc. (NASDAQ

Stifel analyst Laura Prendergast maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and rais

Revolution Medicines NASDAQ: RVMD just landed one of the biggest wins in oncology this year, and the

Revolution Medicines (RVMD) reported earnings 30 days ago. What's next for the stock?

Revolution Medicines (NASDAQ:RVMD) has outperformed the market over the past 5 years by 35.53% on an

Revolution Medicines, Inc. (NASDAQ:RVMD), a global, commercial-stage oncology company dedicated to d

REDWOOD CITY, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD),

Bernie Sanders blasts Big Pharma over $400,000 cancer drugs, warning soaring treatment costs can pus

Short seller BMF Capital disclosed a short position in SELLAS Life Sciences, arguing the market has

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analys

Needham analyst Ami Fadia maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the

Revolution Medicines maintains a strong buy rating following FDA approval of RASONQUE for 2nd-line m

Revolution Medicines (RVMD) secured rapid FDA approval for RASONQUE, a first-in-class oral RAS(ON) i

Revolution Medicines NASDAQ: RVMD said the U.S. Food and Drug Administration has approved daraxonras

UBS analyst Michael Yee maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the pr

Guggenheim analyst Michael Schmitz maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and ra

It's a cancer medication with immense potential. In clinical testing, the pill was shown to double t

Revolution Medicines, Inc. (RVMD) Discusses FDA Approval of RASONQUE for Metastatic Pancreatic Cance

Rasonque wins FDA approval for pancreatic cancer, giving Revolution Medicines its first marketed pro

SELLAS stock gains momentum following FDA approval for Revolution Medicines, highlighting SLS009 pre

Shares of Revolution Medicines are trading higher Thursday morning as a wave of Wall Street firms is

Propanc Biopharma reports strong preclinical data from pancreatic cancer drug, PRP, showing over 90%

Oppenheimer analyst Jay Olson maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform and

RBC Capital analyst Leonid Timashev maintains Revolution Medicines (NASDAQ:RVMD) with a Outperfor

Wedbush analyst Robert Driscoll maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform an

Truist Securities analyst Gregory Renza maintains Revolution Medicines (NASDAQ:RVMD) with a Buy a

As of Aug. 27, 2026, three health care stocks are overbought and could be giving a real warning to m

Evercore ISI Group analyst Cory Kasimov maintains Revolution Medicines (NASDAQ:RVMD) with a Outpe

HC Wainwright & Co. analyst Robert Burns maintains Revolution Medicines (NASDAQ:RVMD) with a

Revolution Medicines (NASDAQ:RVMD) has outperformed the market over the past 5 years by 38.1% on an

FDA approves Revolution Medicines' Rasonque for metastatic pancreatic cancer. Phase 3 trials sho

Bernstein analyst Jeffrey Walch maintains Revolution Medicines (NASDAQ:RVMD) with a Market Perfor

Truist Securities analyst Gregory Renza maintains Revolution Medicines (NASDAQ:RVMD) with a Buy a

Companies also enter a separate regional rights agreement granting BeOne exclusive development and c

Revolution Medicines (NASDAQ:RVMD) has outperformed the market over the past 5 years by 38.08% on an

RBC Capital analyst Leonid Timashev maintains Revolution Medicines (NASDAQ:RVMD) with a Outperfor

Wedbush analyst Robert Driscoll maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform an

Evercore ISI Group analyst Cory Kasimov maintains Revolution Medicines (NASDAQ:RVMD) with a Outpe

Guggenheim analyst Michael Schmidt maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and ra